Aull & Monroe Investment Management Corp Sells 1,130 Shares of Amgen Inc. $AMGN

Key Points

• Aull & Monroe Investment Management Corp reduced its Amgen Inc. holdings by 10.9%, selling 1,130 shares and now owning 9,284 shares valued at approximately $2.59 million.
• Amgen recently announced a quarterly dividend of $2.38, representing an annualized 3.2% yield, with a current payout ratio of 77.84%.
• Analysts have mixed ratings for Amgen, with a consensus rating of "Hold" and a target price of $305.50, while recent price targets range from $272.00 to $333.00.

Aull & Monroe Investment Management Corp cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,284 shares of the medical research company's stock after selling 1,130 shares during the period. Amgen accounts for 1.4% of Aull & Monroe Investment Management Corp's investment portfolio, making the stock its 25th biggest position. Aull & Monroe Investment Management Corp's holdings in Amgen were worth $2,592,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Nuveen LLC bought a new position in Amgen in the 1st quarter valued at $688,868,000. Federated Hermes Inc. boosted its holdings in Amgen by 48.5% in the 1st quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company's stock valued at $634,680,000 after purchasing an additional 665,555 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Amgen by 128.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company's stock valued at $332,017,000 after purchasing an additional 600,096 shares during the period. WoodTrust Financial Corp boosted its holdings in Amgen by 8,223.6% in the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company's stock valued at $166,307,000 after purchasing an additional 588,478 shares during the period. Finally, Kingstone Capital Partners Texas LLC bought a new position in Amgen in the 2nd quarter valued at $156,812,000. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Bank of America raised their price target on shares of Amgen from $261.00 to $272.00 and gave the company an "underperform" rating in a report on Friday, September 26th. Wall Street Zen raised shares of Amgen from a "hold" rating to a "buy" rating in a report on Sunday. Citigroup raised their price target on shares of Amgen from $310.00 to $315.00 and gave the company a "neutral" rating in a report on Wednesday, September 24th. Morgan Stanley raised their price target on shares of Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, Raymond James Financial assumed coverage on shares of Amgen in a research report on Wednesday, September 3rd. They set a "market perform" rating on the stock. Seven analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $305.50.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.76% of the stock is currently owned by insiders.

Amgen Stock Performance

Amgen stock opened at $298.81 on Friday. The firm's fifty day moving average price is $287.14 and its 200-day moving average price is $287.15. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The stock has a market cap of $160.87 billion, a P/E ratio of 24.43, a price-to-earnings-growth ratio of 2.64 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Friday, August 22nd. Amgen's dividend payout ratio (DPR) is presently 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.